Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs Inc (KNW) pioneers non-invasive diagnostic technologies using its patented Bio-RFID and ChromaID systems, transforming traditional medical testing methods. This page serves as the definitive source for verified updates on the company's regulatory progress, clinical validations, and strategic partnerships in the healthtech sector.
Access real-time announcements about wearable device developments, FDA submissions, and peer-reviewed study results. Investors and healthcare professionals will find curated updates on product commercialization timelines, intellectual property expansions, and collaborative research initiatives.
Key content includes earnings call summaries, technology licensing agreements, and analysis of clinical trial outcomes. All materials adhere to journalistic standards for accuracy, providing actionable insights without speculative commentary.
Bookmark this page to monitor Know Labs' advancements in replacing invasive blood tests with electromagnetic-based solutions, including their flagship non-invasive glucose monitor currently under regulatory review.
Rhea-AI Summary
Know Labs, Inc. (KNW) has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit, showcasing significant progress in non-invasive blood glucose monitoring technology. The company's proprietary radiofrequency (RF) dielectric sensor has shown improved accuracy in measuring blood glucose, with recent clinical studies demonstrating stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor. Know Labs aims for FDA clearance and plans to deploy its wearable CGM in large-scale clinical trials to determine real-world applicability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Know Labs, Inc. (KNW) announces positive interim results from its clinical research study on non-invasive blood glucose monitoring in participants with diabetes. The study demonstrates a Mean Absolute Relative Difference (MARD) of 11.1% using the company's proprietary RF sensor, showing promise for future FDA-cleared continuous glucose monitoring devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (KNW) secures a funding agreement for up to $12 million with Lind Global Fund II LP, enabling accelerated development of non-invasive medical diagnostic technology. The investment will support hardware development, expanded data collection, algorithm development, and intellectual property expansion. The company aims to validate its technology in large-scale clinical trials for a non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
Rhea-AI Summary
Know Labs, Inc. announces the KnowU, a wearable non-invasive continuous glucose monitor, incorporating a proprietary sensor for FDA submission. The device is smaller, lighter, and includes machine learning capabilities, aiming to revolutionize diabetes management. The KnowU supports accelerated data collection for FDA clinical trials, offering a future solution for accessible and accurate diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (KNW) reported financial results for Q1 FY 2024, showing a 9.8% reduction in net loss, with a net loss of $3.45 million. Earnings Per Share improved by 50% to a loss of $0.04. The company had cash and cash equivalents of $4.82 million as of December 31, 2023. Know Labs aims to raise funds through equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (KNW) will host a webcast to review business updates and first quarter results for fiscal year 2024 on February 14, 2024. The company is an emerging developer of non-invasive medical diagnostic technology and is focused on developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Summary
Know Labs, Inc. (KNW) will present updated clinical research results and developments of its non-invasive blood glucose monitor at the International Fair of New Technologies in Diabetes. The company will share updates on the latest developments of its non-invasive blood glucose monitor and present results from its ongoing clinical research, with two abstracts accepted for e-poster presentation in the scientific program. Dr. Virend K. Somers of the Mayo Clinic will present the results from the current clinical research protocol, assessing the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference. Know Labs will also sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) during the conference to discuss non-invasive glucose monitoring innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. R&D expenses for FY2023 were $7.73 million dollars, an increase of 43.5% year over year. The company had cash and cash equivalents of $8.02 million dollars, and it expects to raise additional funds through the issuance of equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.33%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) appoints four new members to its Medical and Scientific Advisory Board. Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg bring extensive clinical diabetes management and FDA expertise to the board. They will support the development and FDA clearance of the company's non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Know Labs
NYSE:KNW
KNW Stock Data
1.15M
2.25M
19.93%
5.52%
2.24%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
United States
SEATTLE